OTCPK:DCTH

Stock Analysis Report

Executive Summary

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Risks

  • Delcath Systems has significant price volatility in the past 3 months.
  • Delcath Systems is not covered by any analysts.

Similar Companies

Share Price & News

How has Delcath Systems's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.9%

OTCPK:DCTH

0.5%

US Medical Equipment

-0.02%

US Market


1 Year Return

-98.7%

OTCPK:DCTH

9.9%

US Medical Equipment

1.6%

US Market

DCTH underperformed the Medical Equipment industry which returned 9.7% over the past year.

DCTH underperformed the Market in United States of America which returned 1.9% over the past year.


Share holder returns

DCTHIndustryMarket
7 Day1.9%0.5%-0.02%
30 Day15.6%0.09%2.7%
90 Day-8.3%2.0%1.4%
1 Year-98.7%-98.7%10.8%9.9%3.8%1.6%
3 Year-100.0%-100.0%69.0%63.9%45.2%35.8%
5 Year-100.0%-100.0%136.2%109.3%61.8%44.1%

Price Volatility Vs. Market

How volatile is Delcath Systems's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Delcath Systems undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Delcath Systems is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Delcath Systems has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of DCTH’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Delcath Systems regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Delcath Systems expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Delcath Systems has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of DCTH’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Delcath Systems's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Delcath Systems performed over the past 5 years?

-16.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Delcath Systems does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Delcath Systems's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Delcath Systems's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Delcath Systems has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Delcath Systems has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Delcath Systems improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is Delcath Systems's financial position?


Financial Position Analysis

Delcath Systems's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Delcath Systems's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Delcath Systems has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Delcath Systems's debt level has increased considering it has negative shareholder equity.


Balance Sheet

High level of physical assets or inventory.

Delcath Systems has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Delcath Systems has less than a year of cash runway based on current free cash flow.

Delcath Systems has less than a year of cash runway if free cash flow continues to reduce at historical rates of -3.7% each year.


Next Steps

Dividend

What is Delcath Systems's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Delcath Systems's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Delcath Systems's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Delcath Systems has not reported any payouts.

Unable to verify if Delcath Systems's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Delcath Systems has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Delcath Systems's salary, the management and board of directors tenure and is there insider trading?

3.2yrs

Average management tenure


CEO

Jennifer Simpson (51yo)

3.9yrs

Tenure

US$541,594

Compensation

Dr. Jennifer K. Simpson, Ph.D., M.S.N., C.R.N.P. has been the Chief Executive Officer and President of Delcath Systems, Inc. since October 2015. Dr. Simpson served as an Interim Co-Chief Executive Officer  ...


CEO Compensation Analysis

Jennifer's remuneration is about average for companies of similar size in United States of America.

Jennifer's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.2yrs

Average Tenure

51yo

Average Age

The tenure for the Delcath Systems management team is about average.


Board Age and Tenure

4.9yrs

Average Tenure

62.5yo

Average Age

The tenure for the Delcath Systems board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$9,62523 Oct 18
John Purpura
EntityIndividual
Role
Chief Operating Officer
Executive VP & Global Head of Operations
Shares5,500
Max PriceUS$1.75
BuyUS$8,57523 Oct 18
Roger Stoll
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares4,900
Max PriceUS$1.75
BuyUS$12,94823 Oct 18
Barbra Keck
EntityIndividual
Role
Chief Financial Officer
CFO & Secretary
Shares7,399
Max PriceUS$1.75
BuyUS$12,94823 Oct 18
Jennifer Simpson
EntityIndividual
Role
Chief Executive Officer
President
Shares7,399
Max PriceUS$1.75
BuyUS$11,37523 Oct 18
William Rueckert
EntityIndividual
Role
Member of the Board of Directors
Director
Shares6,500
Max PriceUS$1.75

Ownership Breakdown


Management Team

  • Barbra Keck (41yo)

    CFO & Secretary

    • Tenure: 2.6yrs
    • Compensation: US$374.00k
  • Robin Wagge

    Senior Vice President of Rubenstein Associates

    • Tenure: 0yrs
  • Tom Johnson

    Senior Director of Corporate Communications

    • Tenure: 0yrs
  • John Purpura (58yo)

    Executive VP & Global Head of Operations

    • Tenure: 3.2yrs
    • Compensation: US$385.00k
  • Jennifer Simpson (51yo)

    President

    • Tenure: 3.9yrs
    • Compensation: US$541.59k

Board Members

  • Roger Stoll (76yo)

    Chairman of the Board

    • Tenure: 5yrs
    • Compensation: US$84.00k
  • Bill Rueckert (66yo)

    Director

    • Tenure: 4.8yrs
    • Compensation: US$72.00k
  • John Kaufman

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Jeff Geschwind

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Riccardo Lencioni

    Member of Medical Advisory Board

    • Tenure: 9.8yrs
  • Marco Taglietti (59yo)

    Director

    • Tenure: 4.8yrs
    • Compensation: US$59.00k
  • Alex Eggermont

    Member of Medical Advisory Board

    • Tenure: 11.7yrs
  • Yuman Fong

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Jonathan Zager

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Jennifer Simpson (51yo)

    President

    • Tenure: 3.9yrs
    • Compensation: US$541.59k

Company Information

Delcath Systems, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Delcath Systems, Inc.
  • Ticker: DCTH
  • Exchange: OTCPK
  • Founded: 1988
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$2.011m
  • Shares outstanding: 18.28m
  • Website: https://delcath.com

Number of Employees


Location

  • Delcath Systems, Inc.
  • 1633 Broadway
  • 22nd Floor
  • New York
  • New York
  • 10019
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DCTHOTCPK (Pink Sheets LLC)YesCommon StockUSUSDOct 2001
DV3PDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2001
DV31DB (Deutsche Boerse AG)YesCommon StockDEEUROct 2001

Biography

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company’s investigational products include melphalan hydrochloride for Injec ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 23:34
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.